A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY- MS Baseline Analysis

被引：0

作者：

De Stefano, N. ^{[1
]}

Achiron, A. ^{[2
]}

Barkhof, F. ^{[3
]}

Chan, A. ^{[4
]}

Derfuss, T. ^{[5
]}

Hodgkinson, S. ^{[6
]}

Leocani, L. ^{[7
]}

Montalbant, X. ^{[8
]}

Pratt, A. ^{[9
]}

Schmierer, K. ^{[10
]}

Sellebjerg, F. ^{[11
]}

Vermersch, P. ^{[12
]}

Wiendl, H. ^{[13
]}

Keller, B. ^{[14
]}

Roy, S. ^{[15
]}

机构：

[1] Univ Siena, Dept Neurol & Behav Sci, Siena, Italy

[2] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel

[3] Vrije Univ Amsterdam Med Ctr, Dept Radiol, Amsterdam, Netherlands

[4] Univ Bern, Univ Hosp Berne, Bern, Switzerland

[5] Univ Hosp Basel, Dept Neurol, Basel, Switzerland

[6] Univ New South Wales Med, Ingham Inst Appl Med Res, Sydney, NSW, Australia

[7] Univ Vita Salute San Raffaele, Expt Neurophysiol Unit, Milan, Italy

[8] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada

[10] Queen Mary Univ London, Blizard Inst Neurosci, Barts & London Sch Med & Dent, London, England

[11] Univ Copenhagen, Rigshosp, Danish MS Ctr, Copenhagen, Denmark

[12] Univ Lille, INSERM, U1172, FHU Imminent,CHU Lille, Lille, France

[13] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany

[14] Merck KGaA, Darmstadt, Germany

[15] Merck, Aubonne, Switzerland

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPO1262

引用

页码：685 / 686

页数：2

共 50 条

[31] MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results
Reich, Daniel
Traboulsee, Anthony
Syed, Sana
Xu, Zhixing
Turner, Timothy
Arnold, Douglas
NEUROLOGY, 2023, 100 (17)
[32] MRI outcomes from the long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
Reich, D. S.
Traboulsee, A.
Syed, S.
Xu, Z.
Turner, T. J.
Arnold, D. L.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 334 - 335
[33] Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study
Selmaj, Krzysztof
Langdon, Dawn
Brochet, Bruno
Solari, Alessandra
Havrdova, Eva Kubala
Patti, Francesco
Piehl, Fredrik
Smyk, Andrzej
Lehn, Annette
Nolting, Axel
Montalban, Xavier
Lechner-Scott, Jeannette
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 655 - 657
[34] Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study
Stelmasiak, Z.
Solski, J.
Nowicki, J.
Jakubowska, B.
Ryba, M.
Grieb, P.
MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (06) : 767 - 770
[35] MASTER-2 trial: cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results)
Fox, E. J.
Bass, A. D.
Aldridge, J.
Evans, E.
Lebson, L. A.
Robertson, D.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 700 - 701
[36] Five-year study of adherence to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results
Ramo, C.
Arroyo, E.
Sanchez-Solino, O.
JOURNAL OF NEUROLOGY, 2009, 256 : S125 - S125
[37] Year 1 Performance of Adveva®, a Patient Support Program (PSP) for Patients Taking MAVENCLAD® (cladribine tablets) for Highly Active Relapsing Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK)
Morgan, Kate
Lott, Nadine
Lyons, Marco
NEUROLOGY, 2020, 94 (15)
[38] Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase II ONWARD Study
Montalban, Xavier
Cohen, Bruce
Leist, Thomas
Moses, Harold
Hicking, Christine
Dangond, Fernando
NEUROLOGY, 2016, 86
[39] Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
Oh, J.
Syed, S.
Orogun, L.
Xu, Z.
Turner, T. J.
Fox, R. J.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 342 - 343
[40] Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis
Izquierdo, G.
O'Connor, P.
Montalban, X.
von Rosenstiel, P.
Cremer, M.
de Vera, A.
Sfikas, N.
Francis, G.
Radue, E. W.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 877 - 881

← 1 2 3 4 5 →